FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 312 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR 10 Ways to Provide Support During Breast Cancer Awareness Month September 27, 2019 Merging the Histologic and Molecular Data Into an Integrated Score Significantly... October 11, 2021 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... July 9, 2019 What to Know About Navigating Cancer Care With a Disability: An... May 4, 2023 Load more HOT NEWS EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with... FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among...
